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Genetic mapping of complex diseases to date depends on variations inside or close to the genes that perturb their activities. A strong
body of evidence suggests that changes in gene expression play a key role in complex diseases and that numerous loci perturb gene
expression in trans. The information in trans variants, however, has largely been ignored in the current analysis paradigm. Here we pre-
sent a statistical framework for genetic mapping by utilizing collective information in both cis and trans variants. We reason that for a
disease-associated gene, any genetic variation that perturbs its expression is also likely to influence the disease risk. Thus, the expression
quantitative trait loci (eQTL) of the gene, which constitute a unique ‘‘genetic signature,’’ should overlap significantly with the set of loci
associated with the disease. We translate this idea into a computational algorithm (named Sherlock) to search for gene-disease associa-
tions from GWASs, taking advantage of independent eQTL data. Application of this strategy to Crohn disease and type 2 diabetes pre-
dicts a number of genes with possible disease roles, including several predictions supported by solid experimental evidence. Importantly,
predicted genes are often implicated by multiple trans eQTL with moderate associations. These genes are far from any GWAS association
signals and thus cannot be identified from the GWAS alone. Our approach allows analysis of association data from a new perspective and
is applicable to any complex phenotype. It is readily generalizable to molecular traits other than gene expression, such as metabolites,
noncoding RNAs, and epigenetic modifications.Introduction
Recent application of genome-wide association studies
(GWASs) to complex human diseases led to the discovery
that the majority of disease-associated variants (estimated
to be as high as 88%) are located in noncoding sequences,
potentially affecting gene expression rather than protein
function.1,2 Because of the complexity of gene regulation,
the expression of a gene can be modulated bymutations in
cis (proximal to the gene) and/or in trans (distal to the gene
or on different chromosomes, such as upstream transcrip-
tion/chromatin factors, distal regulatory elements, etc.).3,4
As a result of a large mutational target size (primarily
because of mutations in trans) and the buffering of gene
regulatory systems that helps tolerate expression changes,
genetic variants altering expression levels are common in
populations.5 Indeed, many studies of expression quanti-
tative trait loci (eQTL) demonstrate that the expression
of most genes is influenced bymultiple loci, most of which
act in trans.6–9 Despite their individually small effect sizes,
trans eQTL are collectively important for variation of gene
expression and by some estimates account for a larger pro-
portion of the heritability of gene expression than do cis
eQTL.8,10
Because of their prevalence in the human population,
expression variations, especially those in trans, provide sys-
tematic perturbations of the gene regulatory networks un-
derlying various complex phenotypes, and as such might
reveal important information about the genetic basis of
these phenotypes. Thus there is a pressing need to develop
a general framework to mine the collective information in1Department of Biochemistry and Biophysics, University of California at San
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The Amboth cis- and trans-expression QTL in the context of associ-
ation studies. So far, information from trans variations has
largely been ignored because only cis variants can be as-
signed to their target genes based on proximity by using
the GWAS data alone. The growing collection of eQTL
data for various human tissues makes it possible to asso-
ciate trans variants with target genes.8 Although previous
studies demonstrated the utility of eQTL data for aiding
the analysis of association studies,9,11 most of these used
only cis eQTL located close to the genes. This reflects
some fundamental difficulties of utilizing information in
trans. Because trans eQTL are usually much weaker than
those in cis, the statistical signal of an individual trans
eQTL is difficult to detect—it may fall far below the
genome-wide threshold.9 Another major challenge is the
pleiotropic effect of trans variation. A gene’s trans perturba-
tion may come from the mutation of a regulatory mole-
cule, but this mutation may also affect multiple other
genes.
Here we present a general strategy to infer genes whose
perturbations contribute to the etiology of complex dis-
eases by tapping into statistical information provided
by both cis and trans variations affecting gene expres-
sion. Although individual variants are often weak and
not particularly informative, the overall pattern of
expression variants of a gene can provide a strong statis-
tical signal. A unique aspect of this strategy is that
because we utilize trans variants far from target genes,
it is possible to identify important genes distal to any
GWAS association signals and thus impossible to detect
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To illustrate the basic concept, we consider a gene whose
expression level may influence the risk of a complex dis-
ease. There may be multiple variants in the genome that
affect the expression of this gene in a disease-related tissue
(these are expression SNPs, or eSNPs; technically eSNPs are
only in linkage disequilibrium with the causal variants,
though we do not make the distinction here). A change
of genotype at any of these eSNPs will lead to a change
of expression level, which could in turn alter the disease
risk (Figure 1A). Therefore, many of these eSNPs are likely
to be associated with the disease as well. In general, each
gene has a different set of eSNPs across the genome, with
different effect sizes, reflecting the unique regulatory pro-
gram governing the expression of this gene. The character-
istic pattern of all genetic associations with the expression
of a gene thus constitutes a unique ‘‘genetic signature’’ of
this gene (Figure 1B, top). Similarly, we can define the ge-
netic signature of a phenotype as the statistical association
of all the loci in the genome to the phenotype. If the
expression level of a gene influences the disease risk, the
genetic signature of this gene should match, at least
partially, the genetic signature of the disease (Figure 1B,
bottom).
Our analysis identifies potential gene-disease association
by matching the genetic signature of a gene to that of the
disease, using the GWAS data of the disease and the eQTL
data of a related tissue. It is worth emphasizing that we do
not directly test the statistical relationships between geno-
types, gene expression, and phenotypes, as done by earlier
methods.12 Thus, the eQTL and GWAS data do not have to
come from the same subjects. Instead, the eQTL data pro-
vide information of the genetic signatures of many genes,
and then in an independent GWAS of some phenotype,
the match of a gene’s signature with the GWAS would sug-
gest that the gene plays a role in that phenotype. This is
much like how a detective works (hence the name of our
algorithm, ‘‘Sherlock’’): he compares the fingerprint from
a crime scene (like our GWAS association data) against a
database of fingerprints (like our eQTL data) to determine
the real culprit (the genes whose expression levels influ-
ence the disease risk).
We implement this idea of genetic signature matching
by using a Bayesian statistical framework. Instead of
applying a stringent cutoff, we utilize both strong and
moderate SNPs in the eQTL and GWAS data. The statistical
model allows us to access information in the moderate
SNPs without introducing many false signals. Application
to two well-studied diseases shows the promise of our
approach. We predicted ten genes associated with Crohn
disease (MIM 266600), six of which are highly plausible
based on literature evidence. With an independent
GWAS data set, all but one gene were replicated. Among
our four predicted genes associated with type 2 diabetes
(T2D [MIM 125853]), three are supported by experimental
evidence from literature, and the other is a promising
candidate based on a combined analysis of multiple
genomic data sets.668 The American Journal of Human Genetics 92, 667–680, May 2, 2In summary, our approach allows the analysis of associ-
ation studies from a different perspective and, as we
demonstrate, enables the discovery of genes and pathways
missed by the traditional GWAS analysis. We have con-
structed a web-based resource to facilitate the application
of our method. We collected eQTL data sets from multiple
human tissues and provided the software to search for
gene-disease associations with the disease GWAS as a query
(only p values are needed). With the increasing collection
of eQTL data (as well as QTL of other molecular pheno-
types), we expect that these resources/tools will become
an important platform for interpreting the results from as-
sociation studies.Material and Methods
Statistical Model
Given a gene and the disease of interest, our method tests whether
the expression change of the gene has any effect on the risk of the
disease, using the information of N putative eSNPs of the gene
(passing some low significance threshold in the eQTL data). We
define binary indicator variables Ui and Vi to represent whether
the ith SNP is associated with the expression and the disease trait,
respectively, and a binary indicator variable Z to represent
whether the gene is associated with the disease (Figure 1A). Our
data consist of the p values of SNPs relative to the gene expression
trait (eQTL profile), denoted as vector x, and the p values of the
SNPs relative to the phenotypic trait (GWAS profile), denoted as
y. Although Ui and Vi are not observed, they are related to xi and
yi: when xi(yi) is small (i.e., the SNP is highly significant), it is likely
that Ui(Vi) is true.We use the data x and y to test the hypothesisH0
(i.e., Z ¼ 0) that the gene is not associated with the disease versus
the alternative hypothesis (H1). The dependencies of the statistical
variables are shown in Figure 1D. We describe some intuitions of
our model. Under H0, the gene is irrelevant to the phenotype,
and thus Ui and Vi, are independent in a statistical sense
(Figure 1D, top). Under H1, a true eSNP of the gene is expected
to be associated with the phenotype (Figure 1A). In other words,
whenever Ui is true, Vi should also be true under H1 (Figure 1D,
bottom).
Our inference is based on the posterior ratio, defined as:
PðZ ¼ 1 j x; yÞ
PðZ ¼ 0 j x; yÞ ¼
PðZ ¼ 1Þ
PðZ ¼ 0Þ3
Pðx; y jZ ¼ 1Þ
Pðx; y jZ ¼ 0Þ: (Equation 1)
The first term in the right side is the ratio of the prior probabilities
ofH1 andH0. Typically, the prior ratio is small because only a small
fraction of all genes are expected to be associated with a disease.
The second term is the ratio of model evidence (i.e., the probabil-
ity of data under H1 or H0) called the Bayes factor (BF). The BF is
similar to the familiar likelihood ratio test and does not depend
on the prior probabilities. We will focus on computing the BF
for the inference task.
We assume all SNPs are unlinked (see below for LD blocks).
The BF of the gene expression trait is the product of the BF of all
SNPs:
B ¼
Y
i
Bi ¼
Y
i
P

xi; yi jZ ¼ 1

P

xi; yi jZ ¼ 0
: (Equation 2)013
Figure 1. The Sherlock Algorithm: Matching Genetic Signatures of Gene Expression Traits to that of the Disease to Identify Gene-
Disease Associations
(A) Perturbation of the expression level of a disease-associated gene at any of its eQTL changes the disease risk, and thus the
eQTL tend to be associated with the complex disease as well (the dashed lines). The eQTL associations may contain false
positives, so we use binary indicator variables, U, to represent the true SNP-gene expression relationship; similarly we use indicator
variables, V, for the SNP-disease relationship. Z is a binary variable indicating whether the expression trait influences the disease
risk.
(B) Hypothetic genome-wide association plots of the causal expression trait (top) and a complex disease (bottom). The genetic
signature of the gene expression trait partially overlaps with that of the disease. Red arrows indicate the matched loci.
(C) Alignment of genetic signatures of a gene expression trait and the phenotype. Three different scenarios are shown, represented
by the green, red, and black boxes.
(D) The probabilistic model representing the dependency of the variables. The semantics of the variables U, V, and Z are shown in
(A). When Z ¼ 0, U and V are independent (top). When Z ¼ 1, V depends on both Z and U; if U ¼ 1, then V is also likely to be 1
(bottom). The association statistics of a SNP with respect to the gene expression trait and the disease (x and y) depend on the
hidden variables U and V. Shaded and open circles indicate observed and latent variables, respectively.The likelihood function at each SNP at a given Z is computed by
summing over the hidden variables Ui and Vi:
P

xi; yi jZ
 ¼X
Ui ;Vi
PðUiÞPðVi jZ;UiÞPðxi jUiÞP

yi jVi

: (Equation 3)
Ui is a Bernoulli random variable with the success probability a
(the prior probability of a SNP being associated with the expres-
sion trait). The information about the gene-disease relationship
is encoded in the conditional probability P(Vi j Z, Ui). When
Z ¼ 0 or when Z ¼ 1 and Ui ¼ 0 (a false eSNP), Vi is a Bernoulli
random variable with the success probability b (the prior probabil-
ity of a SNP being associated the phenotype). When Z ¼ 1 and
Ui ¼ 1, according to our discussion before, Vi should also be 1.
The probability terms P(xi j Ui) and P(xi j Vi) reflect the distribution
of p values under the null or alternative hypothesis, and we derive
these distributions in Appendix A.The AmThe Bayes factor defined in Equation 2 can be expressed in terms
of the following variables:
Bi;x ¼ Pðxi jUi ¼ 1Þ
Pðxi jUi ¼ 0Þ Bi;y ¼
P

yi jVi ¼ 1

P

yi jVi ¼ 0
: (Equation 4)
These are the Bayes factors measuring the association of the ith
SNP with the expression and the phenotypic trait, respectively.
We show, in Appendix B, that the BF of the ith SNP in Equation
2 is given by
Bi ¼ 1 a
1 aþ aBi;x þ
aBi;x
1 aþ aBi;x
Bi;y
1 bþ bBi;y: (Equation 5)
Thus the Bayes factor of the gene being tested depends only on the
parameters a, b, and the SNP-level Bayes factors. If Bayesian
inference has been performed in both the eQTL and GWAS anal-
ysis, it is straightforward to combine the resulting BFs to obtain
the BF for the gene.erican Journal of Human Genetics 92, 667–680, May 2, 2013 669
Dealing with Linkage Disequilibrium
For multiple adjacent SNPs, we use a block-level BF in Equation 2.
According to Duan et al.,13 a block is defined as a region of the
genome containing one or more eSNPs associated with the same
gene and having a between-eSNP interval of <500 Kb. Although
this criterion appears somewhat arbitrary, it does not have a large
impact on our analysis primarily because by defining eSNPs with
a certain threshold (p<105),most eSNPsnaturally fall intoblocks.
To combine the BFs of individual SNPs in a block, we follow Servin
and Stephens:14 the block-level BF is themeanof the BFs of all SNPs
in that block. It has been shown that this simple averaging is a
reasonable way of dealing with dependent SNPs in a region.14Model Analysis
To gain some intuition into our method, we show that it leads to a
scoring scheme that is similar to sequence alignment but with an
inherent asymmetry (Figure 1C).15 According to Equation 2, the
total score (logarithm of BF, or LBF) of a gene is the sum of LBF
of each SNP, written as Si ¼ logBi. We discuss the value of Si for
different types of SNPs. We first note that in Equation 5, both a
and b are small numbers (prior probabilities, typically less than
0.01). For a SNP not associated with the gene expression trait,
Bi,x < 1, thus aBi,x  1, according to Equation 5, Si z 0. These
SNPs are not informative, regardless of their association status
with the phenotype. For the informative SNPs, we consider only
very strong eSNPs for simplicity of analysis, aBi,x[ 1, and we
have this approximation:
Si ¼ log Biz log Bi;y
1þ bBi;y: (Equation 6)
We analyze three possible cases depending on the strength of as-
sociation of a SNP with the phenotype. (1) The SNP is strongly
associated with the phenotype bBi,y[ 1, and thus we have Si z
log(1/b). This is a positive number and represents the reward
when the signatures of the two traits match at this SNP. (2) The
SNP is moderately associated with the phenotype Bi,y > 1 but
bBi,y  1, and thus we have Si z logBi,y > 0, representing the
positive but smaller contribution of the SNP. (3) The SNP is not
associated with the phenotype Bi,y < 1, and thus we have the
approximation Si z logBi,y < 0. The negative score represents
the evidence against the gene.
This analysis allows us to understand some properties of the
model. First, the score of any SNP is always bounded by log(1/b),
even if the SNP reaches extremely low p values. Thus the LBF of
a gene is generally not dominated by a single SNP (except for genes
with relatively few eSNPs). Another property of the model is that
the score of a SNP moderately associated with the phenotype
(Siz logBi,y) is not sensitive to the parameter b. Thus we see that
b determines the relative contribution of strong versus weak
SNPs: a smaller value of b favors a single strong SNP over multiple
weaker ones. In general, we believe that genes supported by multi-
ple SNPs are more interesting than those supported by single
strong SNPs, which are probably due to the pleiotropic effects of
SNPs (SNPs independently associated with gene expression and
the phenotype). This suggests that we should use a relatively high
value of b. Meanwhile, this would lead to a conservative estimate
of the Bayes factor (because themaximumLBF per SNP is log(1/b)).Statistical Significance of Bayes Factors
We use simulation to compute the p values of the BFs, a procedure
known as Bayes/non-Bayes compromise.14 To generate the null670 The American Journal of Human Genetics 92, 667–680, May 2, 2distribution of the BFs, we fix the eQTL profiles (the p values of pu-
tative eSNPs) of all the genes and randomize the GWAS data K
times (see below for the details of randomization). The resulting
BFs of all genes over all the K-simulated GWAS data sets then
form the genome-wide null distribution. The p value of each
gene is estimated from the ranking of its BF in this null distribu-
tion. We used K ¼ 50 in our experiments.
To create a randomized GWAS data set, we follow the procedure
described in Liu et al.16 Note that we need to generate randomized
GWAS data only for all the putative eSNPs across all genes, because
other SNPs will not enter the BF calculation. For each gene, we first
divide all its putative eSNPs into blocks, then the p values of each
block are sampled independently: within each block, a multivar-
iate normal (MVN) random vector is sampled with the covariance
matrix matching the LD structure of the block, and the vector is
then converted to p values of SNPs. It has been shown that this
MVN-based approach is a very good approximation of the full per-
mutation procedure (random swapping of cases and controls).16
We choose not to perform permutation of eQTL data because
our statistical procedure depends on the alignment of the eQTL
and GWAS profiles, which are relative to each other. Thus
permuting GWAS data should be equivalent to permuting eQTL
data. In practice, permuting eQTL data is more difficult to imple-
ment, because there are correlated structures in eQTL data that
are difficult to account for and the genotype data of eQTL are
generally not available.Choice of Parameters
Theparametersa andb specify theprior probabilities of a SNPbeing
associated with an expression and a phenotypic trait, respectively.
We further distinguish between cis and trans eSNPs: a should be
higher for cis eSNPs (within 1Mb of the gene) than for trans eSNPs.
Asper theguidelines in literature,17wechose thesevalues:a¼1.03
103 (cis) and 5.03 105 (trans), b ¼ 1.03 103. We provide some
intuitive explanation of these parameters. If we assume there are a
total of one million SNPs, the number of SNPs close to a gene
(within 1 Mb of the coding sequence) is roughly 1,000,000/
3,000,000,0003 2,000,000¼ 1,000 (only order-of-magnitude esti-
mate is made here). Assuming a gene has one cis eSNP, the prior
probability a for SNPs in cis is 1/1,000¼ 103. For trans eSNP, we as-
sume that a genemayhavea relatively largenumberof eSNPs across
the genome, say 50, then the prior probability for SNPs in trans is
50/1,000,000 ¼ 5.03 105. Our selection of the value of b is based
on the following: (1) complex traits are knowntobe associatedwith
hundreds of loci,18 and (2) according to the discussion in the sec-
tion ‘‘Model Analysis,’’ a somewhat high value of b is preferred for
our model. We chose b ¼ 103 in our experiments.
For a SNP associated with a trait, we assume that its effect size
follows a prior normal distribution Nð0;s2aÞ. The default value of
the prior variance parameter is 0.5 for expression traits and 0.2
for phenotypic traits, based on earlier studies.14,17 We note that
these parameters are not necessary if the Bayes factors of SNP asso-
ciations are available from eQTL and GWAS analysis, according to
Equation 5. In addition to these prior parameters, the method also
requires the disease prevalence (5.0 3 104 for Crohn disease and
0.1 for type 2 diabetes) and allele frequencies for each SNP (from
HapMap).Computational Experiments
The eQTL and GWAS data were downloaded from their respective
sources. Because only putative eSNPs are informative, we applied a013
weak cutoff to eQTL based on p values: p < 105 for trans associa-
tions and p < 104 for cis associations. Each gene with at least one
putative eSNP is scored by our program.
In the replication experiment for Crohn disease, we took the
meta-analysis data from IBD Genetics Consortium.19 Because
this data set includes some data we used for predicting disease
genes, we removed it by using the weighted subtraction algorithm
in Zhong et al.,20 and this gave about 2,000 cases and 7,000 con-
trols.
Coexpression Analysis of PURB
The gene expression data were taken from several studies in hu-
mans21–23 and various mouse crosses.12,24,25 The weighted coex-
pression networks were constructed with previously described
methods to derive subnetworks or modules containing highly cor-
egulated genes from each tissue.26 We retrieved all network mod-
ules that contain PURB from all coexpression networks and then
extracted all genes that share module membership with PURB as
PURB-coexpressed genes. These genes are then ranked by how
often they appear with PURB in the same modules.Results
Genetic Signature Matching Algorithm: Sherlock
Our algorithm takes as input the association results from
independent eQTL and GWAS experiments and aims to
identify genes whose expression levels may influence the
disease risk. It uses summary statistics (p values of the asso-
ciations), but does not require the genotype and pheno-
type data. As discussed previously, it assumes that such
genes will have multiple, coincident loci with elevated sig-
nificance in both the GWAS and eQTL data sets (Figures 1A
and 1B). The algorithm scores the significance of the over-
lap by the statistical model described in Material and
Methods.
To see why significant overlap supported bymultiple loci
may imply causality, we consider two alternative sce-
narios.12 In the first scenario, a SNP may affect the disease
and also happen to affect the expression of a gene that has
nothing to do with the disease. However, the likelihood
that multiple disease-associated SNPs happen to affect
the expression of the same gene by chance is very small.
In the second scenario, the disease may compromise the
gene expression patterns of relevant cells, causing some
expression traits to share loci with the disease. This sce-
nario is also unlikely because the eQTL mapping used for
our analysis is usually performed in individuals unrelated
to the GWAS phenotype, and thus the disease loci gener-
ally should not affect gene expression in these samples.
Intuitively, our algorithm performs an alignment of the
genetic signature of one phenotypic trait against an
expression trait. For any SNP, there are potentially three
scenarios, depending on the association of the SNP with
the two traits (Figure 1C). Any SNP that appears to be asso-
ciated with both traits contributes a positive score to the
gene (Figure 1A). Any SNP associated with the expression
trait but not the disease is evidence against the role of
the gene, contributing a negative score. The third type ofThe AmSNPs are associated with the disease but not the expression
of the gene being tested. Because they are not informative
for this gene at the expression level, they will not
contribute to the score of the gene.
We compute the Bayes factor (or its logarithm, LBF) for
each gene (see Material and Methods), which evaluates ev-
idence supporting that the gene is associated versus not
associated with the disease. Specifically, we first compute
the LBF score of each putative eSNP of the gene being
tested, which represents how strongly the SNP supports a
functional role of this gene (see Material and Methods).
The LBF score of a SNP is analogous to the nucleotide
matching scores in sequence alignment, with the sign of
the score corresponding to the three situations described
above (also see Material and Methods, ‘‘Model Analysis’’).
For the cases where multiple SNPs in LD are associated
with a gene, we define a block-level LBF and treat them
as if they were a single SNP (see Material and Methods,
‘‘Dealing with Linkage Disequilibrium’’). Herein, the set
of all eSNPs of a gene are represented by a set of indepen-
dent eSNPs, each of which may actually represent a block
of adjacent SNPs. The total LBF score of a gene is the sum
of LBFs of all SNPs. The value of the LBF score of a gene re-
flects the strength of evidence: for example, a LBF of 2.3
means that the posterior probability of the gene being
associated with the disease is exp(2.3) ¼ 10 times more
likely than the opposite hypothesis assuming that the
two hypotheses are equally likely a priori. In practice, a
gene is a priori far more likely to be unrelated to the dis-
ease, so we generally demand a high LBF (e.g., at least 4.0).
Although BFs can be directly used for inference under a
purely Bayesian framework,27 we take an approach, known
as Bayes/non-Bayes compromise, to compute the p values
of the BFs based on simulations. This has the advantage
that the results are less sensitive to the prior assump-
tions.14 Ideally, the simulation procedure would permute
the case/control labels of the subjects in the GWAS data
to obtain the null distribution of the BFs (we discuss in
Material and Methods why permutation is applied only
to the GWAS and not to the eQTL data). In practice, this
requires genotype data (which is generally not publicly
available) and is computationally intensive. We use an
approximation scheme to generate randomized GWAS
data by modeling the LD structure in the genome with
multivariate normal (MVN) distributions.16 We correct
for multiple hypothesis testing by using the standard Ben-
jamini-Hochberg procedure.28
It is important to emphasize the use of SNPs that fail to
reach traditional thresholds for genome-wide statistical
significance. For both gene expression and phenotypic
traits, recent studies suggest that a large number of loci
may have small effects and fall below the statistical
threshold.8,18 Rather than excluding modest GWAS and
eQTL associations up front, our statistical method takes
them into account and relies on the unlikely occurrence
of chance overlap to assign strong significance at the
gene level. For example, consider a hypothetical geneerican Journal of Human Genetics 92, 667–680, May 2, 2013 671
Figure 2. Quantile-Quantile Plots of the
p Values at the Log. Scale of All Genes
Calculated by Sherlock
(A) Analysis of GWAS data of Crohn dis-
ease with the eQTL of lymphoblast B cells.
(B) Analysis of T2D GWAS data with the
liver eQTL.with four independent eSNPs, each having a p value of
0.001 in the GWAS of a disease. Individually, these SNPs
are far from achieving genome-wide significance. Howev-
er, the chance that all four eSNPs achieve such p values
in GWAS is extremely low: 0.0014 ¼ 1012. Hence, by
combining multiple weak signals, it is possible to achieve
strong statistical confidence.
Overview of Experiments
In each experiment, a GWAS data set (summary statistics or
p values) of some trait is provided and the program runs
the analysis against eQTL data of a relevant tissue in unre-
lated subjects. For all experiments, the program uses a
default set of parameters. For each gene, a LBF score and
its p value based on simulation are computed. The distribu-
tion of the p values of all genes is analyzed to determine
the false discovery rate (FDR) of the predictions. For both
Crohn disease and type 2 diabetes, we reported statistically
significant findings. We further assessed the predictions by
a combination of literature search, replication with inde-
pendent GWAS, and analysis of additional genomic data
sets.
Application to Crohn Disease
Our first experiment is on a GWAS meta-analysis of Crohn
disease (3,230 cases and 4,829 controls)29 uses the eQTL
data from lymphoblast B cells (LBL).13 Crohn disease is
an autoimmune disease of the intestines, one of twomajor
forms of inflammatory bowel disease (IBD). The LBL eQTL
(mainly cis eQTL) has been widely used to support the
analysis of GWAS data of immune-related diseases
including Crohn disease.9,11,30 The original GWAS data
suffers from modest population stratification (l ¼ 1.17),
so we applied the genomic control procedure before
further analysis.31 With only cis eSNPs, we identified a sin-
gle SNP, close to ORMDL3 (MIM 610075), that passes the
respective thresholds in both GWAS and eQTL, consistent
with the previous findings.29 In contrast, Sherlock identi-
fied a number of significant genes: the Q-Q plot of our pre-
dictions for all genes shows a clear excess of genes with
small p values (Figure 2A). To rule out p value inflation,
we created randomized GWAS data by randomly assigning
individuals from the 1000 Genomes Project to ‘‘case’’ and672 The American Journal of Human Genetics 92, 667–680, May 2, 2013‘‘control’’ groups.32 We then per-
formed the same analysis on this ran-
domized data with the real LBL eQTL
data set. The p values from this exper-
iment closely follow the uniform dis-tribution, suggesting that our test is well calibrated
(Figure S1 available online).
At p < 104 (the FDR at this p value threshold is 0.09),
we predicted ten genes (Table 1). Three of the ten, PTGER4
(MIM 601586), ORMDL3, and SLC22A5 (MIM 603377),
were reported in the original GWAS paper and supported
by additional studies.29,33 Below we discuss the remaining
genes and additional analyses. Except for UBE2L3 (MIM
603721), which is supported by a combination of cis
and trans eSNPs, all the remaining genes are supported
only by trans-acting SNPs (Table 2, full results in
Table S1). Importantly, most of these supporting SNPs
have moderate p values in both eQTL and GWAS data
and therefore are generally ignored in the traditional
GWAS analyses.
Notably, the genetic and experimental evidence strongly
suggest possible roles for UBE2L3 and EFS (MIM 609906) in
Crohn disease.UBE2L3was associated with several autoim-
mune diseases, including systemic lupus erythematosus
(MIM 152700), celiac disease (MIM 212750), and rheuma-
toid arthritis (MIM 180300).34 Because autoimmune
diseases often share genetic risk loci,35 the combined evi-
dence supports the role of UBE2L3 in Crohn disease. EFS
has not been associated with autoimmune diseases in pre-
vious GWASs. However, in mouse studies, Efs overexpres-
sion was shown to inhibit T lymphocyte development36
and Efs knockout mice exhibit exaggerated T-cell-mediated
immune responses.37 Remarkably, the knockout mice
develop tissue-specific inflammatory lesions in their small
intestine, a pattern very similar to Crohn disease.37 Addi-
tionally, the target of EFS, the kinase FYN (MIM 137025),
is marginally significant (p ¼ 9.6 3 104, FDR < 0.25).
Together, this evidence suggests that EFS is a strong candi-
date gene for Crohn disease.
Two other genes in our list have well-established im-
mune functions and are possibly related to autoimmune
diseases and IBD. IK (MIM 600549) encodes a cytokine
that downregulates class II MHC antigen whose aberrant
expression has been associated with autoimmune dis-
eases.38 LYNX1 (MIM 606110) encodes a signaling peptide
of nicotinic acetylcholine receptors (nAChR).39 The non-
neuronal cholinergic system plays an important function
in regulating the development and activation of T and B
Table 1. Top Predicted Genes for Crohn Disease
Gene LBF p Value GWAS Hit Supporting Evidence p Value (Rep.)
UBE2L3 7.78 2.2 3 106 no associated with celiac disease, rheumatoid arthritis, and lupus34 4.2 3 106
ORMDL3 5.72 3.3 3 105 yes associated with Crohn disease and ulcerative colitis29,33 1.0 3 106
PTGER4 5.57 3.7 3 105 yes associated with Crohn disease33 3.4 3 105
IK 5.43 4.3 3 105 no regulates class II MHC antigen, which is associated with
autoimmune diseases38
0.75
LYNX1 5.34 4.8 3 105 no agonist of nonneuronal nAchR pathway, which may be
important for IBD39–41
0.014
NUDT4 5.32 4.8 3 105 no NA 3.4 3 105
EFS 5.23 6.1 3 105 no knockout mice exhibit symptoms similar to Crohn disease36,37 0.039
FAM96A 5.19 6.3 3 105 no NA 4.2 3 106
SLC22A5 5.17 6.3 3 105 yes associated with Crohn disease29,33 3.8 3 105
ANAPC2 4.87 9.2 3 105 no NA 0.0006
The LBF column is the logarithm of the Bayes Factor for the genes. The p values refer to the p values of LBFs, calculated from simulations. The ‘‘GWAS hit’’ column
shows whether a gene has been implicated as a candidate gene in previous GWASs. The last column shows the p value of the genes using an independent GWAS
data set of Crohn disease (replication). See the text for details of the supporting evidence.cells.40 Smoking (nicotine) affects both types of IBD, and it
was recently found that these effects are mediated through
alpha7 nAChR,40 a target of LYNX1.39 Furthermore, ago-
nists of alpha7 nAChR affect the disease condition in
experimental colitis (a model of IBD) in mice.41 This evi-
dence suggests a likely role for LYNX1 in Crohn disease
through its effect on nAChR-mediated signaling pathway.
Next, we performed a replication experiment with an in-
dependent GWAS data set for Crohn disease19 and the
same eQTL data set. All genes, except IK, are replicated at
p < 0.05 (Table 1). The extent of replication is highly sig-
nificant (p ¼ 1.8 3 1011, binomial test).
In summary, of the ten genes predicted by our method at
FDR < 0.1, six are known to be associated with Crohn dis-
ease and/or IBD or are strong candidates supported by both
independent discoveries from literature and replication
(UBE2L3, ORMDL3, PTGER4, LYNX1, EFS, and SLC22A5).
One concern is that the genes in the lymphoblasts eQTL
data are enriched with immune-related functions,11 and
thus even a randomly chosen set will hit some plausible
candidate genes. We performed some estimation and a
computational experiment to rule out this possibility. In
this eQTL data set, a total of ~9,200 genes have at least
one putative eSNP (defined by the same thresholds used
for the predicted genes). Assuming there are 1,000 risk
genes of Crohn disease (probably an overestimate), and
even if they all belong to this list of 9,200 genes, the
chance that a randomly chosen gene is associated with
Crohn disease is only 1,000/9,200 ¼ 11%, a ratio far below
that of our predictions (6 out of 10, p ¼ 2.5 3 104, bino-
mial test). Next we randomly sampled two dozen genes
from the set of ~9,200 genes and manually judged their
relevance to Crohn disease by searching literature in the
same way as we did for our candidate genes (Table S2).
Only three genes were found to have some immune func-The Amtion, but none specifically related to IBD, compared with
seven immunity-related genes (the six candidates plus IK)
out of ten in our predictions (p ¼ 0.002, Fisher’s exact
test). Despite some limitations (e.g., manual judgment is
inherently unreliable), the very conservative nature of
our estimation and the strong statistical trends in both an-
alyses suggest that the eQTL data alone cannot explain the
results.
Finally, we explore gene networks underlying Crohn dis-
ease by using information from trans eSNPs that might
reveal potential upstream regulatory genes. We found an
interesting group of genes with moderate statistical sup-
port (nominal p values from .001 to .003; Table S3) that
are associated with the same two independent SNPs in
trans (Figure S2). Most of these genes are related to some as-
pects of autoimmunity (Table S3). Because they are all
affected by the same two eSNPs, this group may be
involved in the same molecular pathway affecting Crohn
disease. Interestingly, one of the two SNPs, rs10248053,
is located inside RELN (MIM 600514), which is associated
with the age of onset of multiple sclerosis (MIM 126200),
an autoimmune disease,42 and may also be involved in a
subtype of T cell leukemia.43
Application to Type 2 Diabetes
We next performed an experiment on the GWAS of T2D
from DIAGRAM (4,549 cases and 5,579 controls)44 by us-
ing liver eQTL.45 Previous studies that used the liver data
have provided insights on T2D, though only cis eSNPs
were utilized.20,45 The p values of the vast majority of
the genes closely track the uniform distribution, with
about a dozen genes significantly above the diagonal
line in the Q-Q plot (Figure 2B). The analysis using
permuted GWAS data confirmed the absence of p value
inflation (Figure S1). At p < 104 (FDR 0.3 at this p valueerican Journal of Human Genetics 92, 667–680, May 2, 2013 673
Table 2. Supporting SNPs for Some of the Predicted Genes of Crohn Disease
Gene SNP SNP Location Proximity eQTL p Value GWAS p Value LBF
UBE2L3 (7) rs2283790 chr22: 20,286,653 cis 6.0 3 106 8.9 3 106 6.7
rs7735799 chr5: 84,248,096 trans 3.0 3 106 7.2 3 104 1.3
EFS (16) rs2154490 chr21: 29,837,833 trans 6.0 3 106 3.5 3 104 2.6
rs8044972 chr16: 75,957,583 trans 1.0 3 106 2.0 3 102 1.9
rs6843282 chr4: 32,433,817 trans 9.0 3 106 2.0 3 103 1.4
rs2210054 chr14: 33,091,890 trans 1.0 3 105 5.9 3 103 0.8
LYNX1 (5) rs921719 chr8: 126,615,379 trans 1.0 3 105 7.8 3 105 3.7
rs11205709 chr1: 50,581,881 trans 1.0 3 105 2.8 3 103 1.1
rs1998564 chr13: 107,034,232 trans 1.0 3 106 1.2 3 102 0.7
A SNP is called in cis of a gene if it is located within 1 Mb of the transcription start site of this gene. Each SNP in the table actually represents a block of adjacent
eSNPs (chosen to be the one with the highest LBF). The number in parentheses in the Gene column shows the total number of putative eSNP blocks (defined as
p < 105 in the eQTL data) of that gene. The LBF column shows the LBF of individual SNP (see Material and Methods). Only SNPs with LBF greater than 0.5 are
shown.cutoff), we predicted four genes (Tables 3 and 4). Two of
the four, PURB (MIM 608887) and GNB5 (MIM 604447),
are supported only by trans-acting SNPs. Similar to Crohn
disease, most of the supporting SNPs have only moderate
statistical significance in both the GWAS and eQTL data
sets.
We found literature evidence supporting three of our pre-
dicted genes. TSPAN8 (MIM 600769) is reported in the orig-
inal DIAGRAM study and replicated by subsequent
GWASs.44 In an experimental mouse study, haploinsuffi-
ciency (deletionof a single copy) ofGnb5 (themousehomo-
log of GNB5) caused late-onset obesity, insulin resistance,
and liver steatosis on a normal diet, phenotypes strongly
resembling human metabolic syndrome and T2D.46 In
addition, a closely related gene, GNB3 (MIM 139130), is
shown to be associated with obesity, insulin resistance,
and glucose tolerance in several studies.47 A SNP close to
JAZF1 (MIM 606246) was associated with T2D,44,48 and
deletion of Jazf1 in mice leads to increased fat mass and in-
sulin resistance.49 Interestingly, the SNP rs849134 (close to
the supporting cis eSNP rs1635852 of JAZF1, Table 4)was re-
ported to be strongly associated with both T2D and the
expression of JAZF1 in adipose tissue in the DIAGRAM
study.48 The replication of this finding in liver
(rs1635852, associated with T2D and liver expression of
JAZF1) along with the additional trans eSNP from our anal-
ysis provides independent evidence of JAZF1.
We assembled genomic data from a number of mouse
studies to assess the putative role of PURB in T2D. The
expression of Purb in multiple tissues (liver, adipose, mus-
cle, and islet) has been previously found to influence a
number of metabolic phenotypes including fat mass, fat
to body weight ratio, glucose level, insulin level, glucose
to insulin ratio, and oral glucose tolerance test in sixmouse
crosses via a genetic causality test (FDR 10%).12,24,25,50 The
fact that this relationship was consistently discovered in
different tissues and in different genetic backgrounds pro-674 The American Journal of Human Genetics 92, 667–680, May 2, 2vides good evidence of a putative role of PURB in T2D. We
also surveyed genes coexpressed with PURB by using previ-
ously described tissue-specific coexpression networks con-
structed from expression data in human and various
mouse crosses (see Material and Methods). Genes within
a given network module have been found to share similar
biological functions. The top gene coexpressed with PURB
is SERPINF1 (MIM 172860, appeared in >30% of the 128
coexpression modules containing PURB), a strong candi-
date gene for T2D.51,52 The strong coexpression between
the two genes thus lends further support to PURB as a
possible T2D-associated gene.
We also analyzed the supporting trans eSNPs of the pre-
dicted genes of T2D. One supporting eSNP of PURB,
rs319598 (Table 4), is located in the promoter of PCBD2
(MIM 609836), which is a cofactor of HNF1A (MIM
142410), a liver-specific transcription factor. Mutations of
HNF1A are responsible for 30%–70% of the cases of matu-
rity-onset diabetes of the young (MODY [MIM 606391]), a
rare form of T2D.53 In another example, we focused on
NDRG2 (MIM 605272), a gene slightly below our threshold
(p¼ 3.03104, ranked sixth, not shown inTable 3) but bio-
logically interesting because of its role in b cell protection.54
One of the two supporting eSNPs ofNDRG2, rs7334, is close
to the 30 end of EGFR (MIM 131550). The EGFR signaling
pathway plays a key role in pancreatic beta cell develop-
ment: even a modest attenuation leads to a severe defect
in b cells, causing diabetes.55 These analyses thus further
support PURB andNDRG2 as T2D candidate genes and sug-
gest the possible mechanism of their actions, by linking
them to the well-established diabetes pathways.Discussion
We have proposed a general strategy for genetic mapping
that integrates information from GWAS with eQTL data.013
Table 3. Top Predicted Genes for Type 2 Diabetes
Gene LBF p Value GWAS Hit Supporting Evidence
TSPAN8 6.08 9.4 3 106 yes associated with T2D
in GWAS48
PURB 6.07 9.4 3 106 no expression is causal to
T2D-related phenotypes
(see text)
GNB5 4.97 8.9 3 105 no deletion leads to T2D
symptoms46,47
JAZF1 4.93 9.5 3 105 yes deletion leads to
T2D symptoms;49
GWAS association48
The LBF column is the logarithm of the Bayes Factor for the genes. The p values
refer to the p values of LBFs, calculated from simulations. The ‘‘GWAS Hit’’ col-
umn shows whether a gene has been implicated as a candidate gene in previ-
ous GWAS. See the text for details of the supporting evidence.Instead of testing individual variants close to a gene, we
pool the information in all variants, mostly in trans, that
perturb the expression of the gene to infer its role in a com-
plex disease. The major difficulties for utilizing trans vari-
ants to date are their relatively small effects and the pleio-
tropicity of their influences. We overcome these by
utilizing the statistical pattern of multiple trans variants,
much like a detective using a fingerprint to identify a sus-
pect. Our experiments in Crohn disease and T2D demon-
strate the benefits of this approach. Our predictions are
often supported by moderate SNPs acting in trans (Tables
2 and 4) and thus are not possible to identify by the tradi-
tional methods. We believe this general framework signif-
icantly extends existing approaches to genetic mapping
of complex phenotypes. Both theoretical considerations
(complexity of gene regulatory networks) and empirical
studies support the importance of trans variants affecting
gene expression traits. By accessing this large amount of
so-far unutilized information, our method could greatly
expand our ability to derive new insights from association
studies.
Application of our method to two complex diseases led
to findings that are supported by multiple lines of evi-
dence. First, for both Crohn disease and T2D, there are
clear enrichments of candidate genes from the overall p
value distributions (Figure 2). Second, in the study of
Crohn disease, we show that all but one of ten predicted
genes are replicated in an independent GWAS data set.
Third, among our predictions not implicated in human
studies before, genetic manipulations of Efs and Gnb5 in
experimental mice lead to phenotypes highly consistent
with the roles in Crohn disease and T2D, respectively.
The collective evidence thus supports our approach as a
promising strategy to extract insights from GWASs.
From a population genetic perspective, our strategy
provides a significant addition to existing paradigms for
genetic mapping. Selection pressure generally keeps prox-
imal, large-effect variants at very low frequencies in the
population.56 This largely explains the observation thatThe Ammost common variants identified in GWASs have small ef-
fect sizes.57 Major efforts are underway to identify rare var-
iants with larger effects by using exome or whole-genome
sequencing. Although this has led to a number of discov-
eries forMendelian diseases, its success in complex diseases
is modest,58 presumably reflecting large sample size re-
quirements for rare variants. Our strategy is based on the
notion that distal variations that only weakly perturb the
expression of a gene may survive at significant frequencies
in the population because of weaker selection and that
there could be many such variations across the genome.
Although such weak genetic perturbations may manifest
as only modest associations in both the eQTL analysis
and the GWAS of a disease, the genes they perturb can
play an important role in the disease. In our analysis,
although the supporting SNPs of EFS and GNB5 are all in
trans with modest associations, genetically manipulated
mice exhibit severe abnormalities resembling Crohn dis-
ease and T2D, respectively.37,46 Thus our strategy of
genetic mapping is capable of finding hidden gene-disease
associations by leveraging the collective signals of multiple
modest perturbations across the genome.
Our work laid down a general framework for using data
from association studies of quantitative molecular traits
to interpret GWASs of complex diseases. Many eQTL
studies in human have been performed,9,30 but the vast
amount of information in the trans eQTL remains unuti-
lized. There are also efforts on mapping QTL of other
molecular traits, such as metabolites59 and epigenetic
modifications.60 Misregulation in these aspects could be
important drivers of complex diseases.61 Our method is
readily generalizable to these data sets, by defining the ge-
netic signatures of molecular traits and by matching these
signatures to that of the disease.
Our method employs a rigorous statistical framework,
leading to major advantages over simple, heuristic
methods (e.g., count the number of SNPs shared by the
expression and disease traits, defined via some p value
threshold). First, both strong and weak loci are taken into
account with proper weighting. We incorporate all GWAS
associations into the analysis without relying on arbitrary
significance thresholds. This is crucial because most of the
supporting SNPs in our findings are moderately associated
with the expression trait and phenotype but fail to reach
genome-wide significance threshold (Tables 2 and 4). Sec-
ond, our method in general does not permit individual
SNPs to dominate the results (see ‘‘Model Analysis’’ in Ma-
terial and Methods), a common issue when testing associ-
ation of a set of SNPs in GWASs.62 Third, the inherent
asymmetry of the relationship between the gene and the
disease is reflected in our model. A SNP associated with
gene expression but not the disease is used as evidence
against the gene, and a SNP associated with the disease
but not gene expression is treated as noninformative.
An important decision to make when using our tool is
the selection of phenotype-appropriate eQTL data sets.
For some common diseases, it may be straightforward toerican Journal of Human Genetics 92, 667–680, May 2, 2013 675
Table 4. Supporting SNPs for the Predicted Genes for Type 2 Diabetes
Gene SNP SNP Location Proximity eQTL p Value GWAS p Value LBF
TSPAN8 (5) rs7298255 chr12: 69,714,336 cis 2.7 3 109 1.3 3 106 6.4
PURB (14) rs319598 chr5: 134,268,134 trans 4.5 3 106 3.9 3 105 4.9
rs11022347 chr11: 12,391,558 trans 7.3 3 106 2.2 3 103 1.3
rs2028967 chr2: 142,990,138 trans 6.4 3 106 5.0 3 103 0.9
GNB5 (7) rs2021910 chr6: 85,141,735 trans 1.8 3 106 3.0 3 104 3.8
rs13105547 chr4: 52,974,359 trans 5.5 3 107 2.1 3 102 1.0
JAZF1 (10) rs1635852 chr7: 28,155,936 cis 3.6 3 106 2.2 3 105 4.8
rs885720 chr12: 12,139,366 trans 2.1 3 106 2.7 3 102 0.6
A SNP is called in cis of a gene if it is located within 1 Mb of the transcription start site of this gene. Each SNP in the table actually represents a block of adjacent
eSNPs (chosen to be the one with the highest LBF). The number in parentheses in the Gene column shows the total number of putative eSNP blocks (defined as
p < 105 in the eQTL data) of that gene. The LBF column shows the LBF of individual SNP (see Material and Methods). Only SNPs with LBF greater than 0.5 are
shown.choose relevant disease tissues, e.g., brain for psychiatric
diseases. The results of our method also provide a quantita-
tive measure of success (the number of significant genes
above a certain FDR) and hence an indication of how infor-
mative a particular eQTL data set is. In general, we believe
that there is probably not a single ‘‘correct’’ tissue; rather,
multiple tissues may be informative to different degrees.
For instance, it was reported recently that skin, adipose,
and blood cells share a substantial fraction of eQTL.63
Thus, it is possible that skin or blood eQTLmay provide in-
formation for metabolic diseases. An important future
challenge is to characterize the similarity and difference
of eQTL across tissues and to develop an analytic frame-
work to integrate information from multiple tissues.
Schadt et al. pioneered the use of eQTL for understand-
ing genetics of complex traits.12,61 In experimental ani-
mals, it is possible to perform genotyping, expression
profiling, and phenotyping on the same individuals, al-
lowing researchers to analyze patterns of correlation and
dependency among variables to infer causal relation-
ships.12 It is difficult, however, to apply this strategy to
human studies. Expression profiling of disease-related tis-
sues in human subjects is generally costly and often not
feasible. Another difficulty is the challenge of mapping
trans eQTL in human;9 as a result, most of the existing
studies utilizing human eQTL data focus on associations
in cis,9,11 with only a few exceptions.64,65 With our
approach, we have circumvented these problems and
demonstrated that, even without all three types of data
in the same samples, it is possible to infer associations be-
tween expression traits and diseases.
In our experiments with T2D, unlike Crohn disease, we
predicted a small number of genes at a relatively high error
rate (four genes at FDR < 0.3). Several factors might
contribute to this lower level of statistical evidence: (1)
our T2D analysis is based on liver eQTL data, although
more relevant tissues for T2D are probably adipose and
pancreatic tissues; and (2) we were unable to perform
imputation because of lack of genotype data, thus reducing676 The American Journal of Human Genetics 92, 667–680, May 2, 2the overlap between eQTL and GWAS data sets and the po-
wer of ourmethod.We believe the results still provide valu-
able information from existing data. The predictions create
a short list of candidate genes; when combining with addi-
tional evidence, some interesting hypotheses may emerge.
One of our predictions, PURB, for instance, is supported by
multiple human and mouse genomic data sets, and there-
fore is an interesting candidate for follow-up analysis.
Although current GWASs typically use only common
SNPs measured by array-based genotyping platforms,
next-generation sequencing (NGS) technologies provide
a window into other types of genetic variation, including
rare SNPs, copy-number variants, and indels. Our strategy
of matching genetic signatures is based on very general
principles and therefore can be easily adapted to these
new forms of genetic variations.Appendix A: The Null and Alternative Distributions
of the Association Statistics of SNPs
For a given SNP, let T be its association test statistic (p value
can be converted to T, assuming a standard normal distri-
bution) for a trait, either an expression trait or phenotype.
We use M to denote the model: M ¼ 0 corresponds to the
null model of no association between the SNP and the
trait, and M ¼ 1 corresponds to the alternative model.
We need to compute the probability distribution,
P(T j M). In the null model, typically, P(T j M ¼ 0) follows
the standard normal distribution. In the alternative model,
the distribution P(T jM ¼ 1) depends on the statistical test
throughwhich T is derived and the effect size of the SNP, as
explained below.Binary Trait
We assume the Armitage trend test was used to derive the
test statistics. We follow the notations in Slager and
Schaid:66 for a given SNP, there are two alleles, A for the
high-risk allele and a for the other. The frequency of the013
ith genotype (i ¼ 0,1,2 is the number of A alleles) in cases is
pi, and its frequency in controls is qi. The number of case
and control individuals with each genotype are shown in
Table A1.Table A1. The Number of Individuals with Given Genotypes
Genotype aa aA AA Total
Cases r0 r1 r2 R
Controls s0 s1 s2 S
Total n0 n1 n2 NWe define a variable xi ¼ i, the number of A alleles in a
genotype, the Armitage trend test can be written as
T ¼ U= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃVarðUÞp , where
U ¼
X
i
xi

S
N
ri  R
N
si

: (Equation A1)
Under the null hypothesis of no association, the mean of
U(m0) is 0 and its variance is given by
66
s20 ¼ Nfð1 fÞ
"X
i
x2i qi 
 X
i
xiqi
!2#
; (Equation A2)
where f ¼ R/N is the fraction of cases in the sample. Based
on the central limit theorem, the asymptotic distribution,
T ¼ U=s0  Nð0;1Þ.
Under the alternative hypothesis of association, the
mean and variance of U are given by66
m1 ¼ Nfð1 fÞ
X
i
xi

pi  qi

(Equation A3)
s21 ¼ Nfð1 fÞ2
"X
i
x2i pi 
 X
i
xipi
!2#
þNf2ð1 fÞ
3
"X
i
x2i qi 
 X
i
xiqi
!2#
: (Equation A4)
Thus, T follows normal distribution:
T ¼ U
s0
 N

m1
s0
;
s21
s20

: (Equation A5)
The parameters pi and qi are unknown, but they are
related to the effect size and allele frequency of the SNP
in the population. For the ith genotype, let fi be its pene-
trance (the probability of disease given the genotype)
and gi be its frequency in the population. Then pi and qi
are related to fi and gi through the Bayes theorem:
pi ¼ figiP
i
figi
; qi ¼

1 fi

giP
i

1 fi

gi
: (Equation A6)
The sum Sifigi is also called disease prevalence, K. Assuming
Hardy-Weinberg equilibrium, the genotype frequencies are
simply related to p, the frequency of the risk alleleThe Am(assumed known, e.g., from HapMap). Suppose the effect
size (the logarithm of the odds ratio of the risk allele) is
b, the relative risk is then approximately g ¼ eb. Assuming
the multiplicative genetic model, we have f1 ¼ gf0 and f2 ¼
g2f0. With the fact K ¼ Sifigi, we could solve f0:
f0 ¼ K½gpþ ð1 pÞ2 (Equation A7)
In summary, given K and p, pi and qi can be expressed as
functions of b. Plug in pi and qi to equations of m1, s1, we
can write m1, s1 as functions of b as well: m1(b; K, p) and
s1(b; K, p). Because b is unknown, we assume a prior distri-
bution of b: bjM ¼ 1  Nð0;s2aÞ and integrate out b in the
distribution P(T j M ¼ 1):
Pðt jM ¼ 1Þ ¼
Z
Pðt j bÞPðb jM ¼ 1Þdb
¼
Z
N

t jm1ðbÞ
s0
;
s21ðbÞ
s0

N

b j0; s2a

db;
(Equation A8)
WhereN(tj.) is the p.d.f. of the normal distribution. A com-
mon choice of the prior distribution is s2a ¼ 0:2.17
Quantitative Trait
For an association study of a quantitative trait, we assume a
z-test of the linear regression coefficient is used. Specif-
ically, we have the following regression:
yi ¼ mþ bxi þ εi; (Equation A9)
where xi and yi are the genotype and phenotype of the i
th
subject in the sample, respectively, and εi ~ N(0,s
2) is the
error term. The statistic test of whether b ¼ 0 is: T ¼ b1/
s(b1), where b1 is the MLE of b. The variance of b1 is given
by
s2ðb1Þ ¼ s
2P ðxi  xÞ2 ¼
s2
2Npð1 pÞ; (Equation A10)
where N is sample size and p is the allele frequency
(assuming HWE). T follows standard normal distribution
under M ¼ 0: T ¼ b1/s(b1) ~ N(0,1). In this calculation,
we assume that s2 is known. If this is not true, we need
to replace s2 with its MLE, s2 in T. However, with large
sample size (which is often the case in large GWASs), the
two are close, so for simplicity, we will use s2 instead. Un-
derM¼ 1, we assume the prior distribution b  Nð0;s2as2Þ,
according to Servin and Stephens,14 where sa reflects the
typical effect size compared with the standard deviation
of the quantitative trait. With the distribution b1 ~
N(b,s2(b1)), we have
Pðb1 jM ¼ 1Þ ¼
Z
Pðb1 j bÞPðb jM ¼ 1Þdb
¼
Z
N

b1 j b; s2ðb1Þ

N

b j 0; s2as2

db
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It is easy to show that b1 underM ¼ 1 follows the normal
distribution b1  Nð0;s2ðb1Þ þ s2as2Þ, thus
T ¼ b1
sðb1Þ  N

0;1þ 2Npð1 pÞs2a

: (Equation A12)
The hyperparameter of the prior distribution, sa, is fixed
at 0.5 in our experiments, based on the earlier study of
Bayesian association mapping of quantitative traits.14
Appendix B: Relating the Bayes Factors of Genes to
the SNP-Level Bayes Factors in eQTL and GWAS
Data
Under the null hypothesis of no gene-disease relationship
(Z ¼ 0), the eQTL and GWAS data are independent
(Figure 1D), and we thus have the model evidence of the
null hypothesis:
Pðx; y jH0Þ ¼
YN
i¼1
Pðxi jH0ÞP

yi jH0
 ¼YN
i¼1
f0ðxiÞg0

yi

;
(Equation A13)
where the two functions describe the probability of eQTL
and GWAS summary statistics, respectively:
f0ðxiÞ ¼ Pðxi jH0Þ ¼ ð1 aÞPðxi jUi ¼ 0Þ þ aPðxi jUi ¼ 1Þ
(Equation A14)
g0

yi
 ¼ Pyi jH0 ¼ ð1 bÞPyi jVi ¼ 0þ bPyi jVi ¼ 1:
(Equation A15)
Under the alternative hypothesis (Z ¼ 1), we plug in the
relevant terms to Equation 3:
P

xi; yi jH1
 ¼ ð1 aÞPðxi jUi ¼ 0Þg0yi
þ aPðxi jUi ¼ 1ÞP

yi jVi ¼ 1

:
(Equation A16)
Divide the model evidence of H1 at the i
th SNP over that
of H0, we have
Bi ¼
P

xi; yi jH1

P

xi; yi jH0

¼ ð1 aÞPðxi jUi ¼ 0Þg0

yi
þ aPðxi jUi ¼ 1ÞPyi jVi ¼ 1
f0ðxiÞg0

yi
 :
(Equation A17)
Eliminate the common terms in the numerator and the
denominator, and we have Equation 5 shown in the
main text. The gene level BF is simply the product of Bis.Supplemental Data
Supplemental Data include two figures and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
The authors wish to thank Kathleen Giacomini, Sook Wah Yee,
Saunak Sen, Mark Seielstad, Neil Risch, and Jiashun Zheng for678 The American Journal of Human Genetics 92, 667–680, May 2, 2helpful discussions and technical support. We would also like to
thank the DIAGRAM consortium for providing the T2D GWAS
data and Mark McCarthy for valuable comments on the manu-
script. This work was supported by National Institutes of Health
grants R01(GM070808) and U19(GM61390), the NIH Center for
Systems and Synthetic Biology (P50 GM081879), and a Packard
Fellowship in Science and Engineering to H.L.
Received: October 10, 2012
Revised: March 7, 2013
Accepted: March 25, 2013
Published: May 2, 2013Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://browser.1000genomes.org
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
Sherlock, http://sherlock.ucsf.edu/References
1. Hindorff, L.A., Sethupathy, P., Junkins, H.A., Ramos, E.M.,
Mehta, J.P., Collins, F.S., and Manolio, T.A. (2009). Potential
etiologic and functional implications of genome-wide associa-
tion loci for human diseases and traits. Proc. Natl. Acad. Sci.
USA 106, 9362–9367.
2. Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A.,
Doyle, F., Epstein, C.B., Frietze, S., Harrow, J., Kaul, R., et al.;
ENCODE Project Consortium. (2012). An integrated encyclo-
pedia of DNA elements in the human genome. Nature 489,
57–74.
3. Vidal, M., Cusick, M.E., and Baraba´si, A.L. (2011). Interactome
networks and human disease. Cell 144, 986–998.
4. Sanyal, A., Lajoie, B.R., Jain, G., and Dekker, J. (2012). The
long-range interaction landscape of gene promoters. Nature
489, 109–113.
5. Wittkopp, P.J., Haerum, B.K., and Clark, A.G. (2008). Regulato-
ry changes underlying expression differences within and
between Drosophila species. Nat. Genet. 40, 346–350.
6. Brem, R.B., and Kruglyak, L. (2005). The landscape of genetic
complexity across 5,700 gene expression traits in yeast. Proc.
Natl. Acad. Sci. USA 102, 1572–1577.
7. Yvert, G., Brem, R.B., Whittle, J., Akey, J.M., Foss, E., Smith,
E.N., Mackelprang, R., and Kruglyak, L. (2003). Trans-acting
regulatory variation in Saccharomyces cerevisiae and the role
of transcription factors. Nat. Genet. 35, 57–64.
8. Cheung, V.G., Nayak, R.R., Wang, I.X., Elwyn, S., Cousins,
S.M., Morley, M., and Spielman, R.S. (2010). Polymorphic
cis- and trans-regulation of human gene expression. PLoS
Biol. 8, e1000480.
9. Montgomery, S.B., and Dermitzakis, E.T. (2011). From expres-
sion QTLs to personalized transcriptomics. Nat. Rev. Genet.
12, 277–282.
10. Price, A.L., Patterson, N., Hancks, D.C., Myers, S., Reich, D.,
Cheung, V.G., and Spielman, R.S. (2008). Effects of cis and
trans genetic ancestry on gene expression in African Ameri-
cans. PLoS Genet. 4, e1000294.
11. Nicolae, D.L., Gamazon, E., Zhang, W., Duan, S., Dolan, M.E.,
and Cox, N.J. (2010). Trait-associated SNPs are more likely to013
be eQTLs: annotation to enhance discovery from GWAS. PLoS
Genet. 6, e1000888.
12. Schadt, E.E., Lamb, J., Yang, X., Zhu, J., Edwards, S., Guhatha-
kurta, D., Sieberts, S.K., Monks, S., Reitman, M., Zhang, C.,
et al. (2005). An integrative genomics approach to infer causal
associations between gene expression and disease. Nat. Genet.
37, 710–717.
13. Duan, S., Huang, R.S., Zhang, W., Bleibel, W.K., Roe, C.A.,
Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E., Cox,
N.J., and Dolan, M.E. (2008). Genetic architecture of tran-
script-level variation in humans. Am. J. Hum. Genet. 82,
1101–1113.
14. Servin, B., and Stephens, M. (2007). Imputation-based anal-
ysis of association studies: candidate regions and quantitative
traits. PLoS Genet. 3, e114.
15. Durbin, R., Eddy, S.R., Krogh, A., and Mitchison, G. (1998).
Biological Sequence Analysis: Probabilistic Models of Proteins
and Nucleic Acids (Cambridge, UK: Cambridge University
Press).
16. Liu, J.Z., McRae, A.F., Nyholt, D.R., Medland, S.E., Wray, N.R.,
Brown, K.M., Hayward, N.K., Montgomery, G.W., Visscher,
P.M., Martin, N.G., and Macgregor, S.; AMFS Investigators.
(2010). A versatile gene-based test for genome-wide associa-
tion studies. Am. J. Hum. Genet. 87, 139–145.
17. Stephens, M., and Balding, D.J. (2009). Bayesian statistical
methods for genetic association studies. Nat. Rev. Genet. 10,
681–690.
18. Lango Allen, H., Estrada, K., Lettre, G., Berndt, S.I., Weedon,
M.N., Rivadeneira, F., Willer, C.J., Jackson, A.U., Vedantam,
S., Raychaudhuri, S., et al. (2010). Hundreds of variants clus-
tered in genomic loci and biological pathways affect human
height. Nature 467, 832–838.
19. Franke, A., McGovern, D.P., Barrett, J.C., Wang, K., Radford-
Smith, G.L., Ahmad, T., Lees, C.W., Balschun, T., Lee, J., Rob-
erts, R., et al. (2010). Genome-wide meta-analysis increases to
71 the number of confirmed Crohn’s disease susceptibility
loci. Nat. Genet. 42, 1118–1125.
20. Zhong, H., Yang, X., Kaplan, L.M., Molony, C., and Schadt,
E.E. (2010). Integrating pathway analysis and genetics of
gene expression for genome-wide association studies. Am. J.
Hum. Genet. 86, 581–591.
21. Greenawalt, D.M., Dobrin, R., Chudin, E., Hatoum, I.J., Suver,
C., Beaulaurier, J., Zhang, B., Castro, V., Zhu, J., Sieberts, S.K.,
et al. (2011). A survey of the genetics of stomach, liver, and ad-
ipose gene expression from a morbidly obese cohort. Genome
Res. 21, 1008–1016.
22. Yang, X., Zhang, B., Molony, C., Chudin, E., Hao, K., Zhu, J.,
Gaedigk, A., Suver, C., Zhong, H., Leeder, J.S., et al. (2010). Sys-
tematic genetic and genomic analysis of cytochrome P450
enzyme activities in human liver. Genome Res. 20, 1020–
1036.
23. Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A.S.,
Zink, F., Zhu, J., Carlson, S., Helgason, A., Walters, G.B., Gun-
narsdottir, S., et al. (2008). Genetics of gene expression and its
effect on disease. Nature 452, 423–428.
24. Chen, Y., Zhu, J., Lum, P.Y., Yang, X., Pinto, S., MacNeil, D.J.,
Zhang, C., Lamb, J., Edwards, S., Sieberts, S.K., et al. (2008).
Variations in DNA elucidate molecular networks that cause
disease. Nature 452, 429–435.
25. Derry, J.M., Zhong, H., Molony, C., MacNeil, D., Guhatha-
kurta, D., Zhang, B., Mudgett, J., Small, K., El Fertak, L., Gui-
mond, A., et al. (2010). Identification of genes and networksThe Amdriving cardiovascular and metabolic phenotypes in a mouse
F2 intercross. PLoS ONE 5, e14319.
26. Zhang, B., and Horvath, S. (2005). A general framework for
weighted gene co-expression network analysis. Stat. Appl.
Genet. Mol. Biol. 4, e17.
27. Wakefield, J. (2008). Reporting and interpretation in genome-
wide association studies. Int. J. Epidemiol. 37, 641–653.
28. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false
discovery rate - a practical and powerful approach to multiple
testing. J. Roy. Stat. Soc. B Met. 57, 289–300.
29. Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H.,
Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, K.D., Barmada,
M.M., et al.; NIDDK IBD Genetics Consortium; Belgian-
French IBD Consortium; Wellcome Trust Case Control Con-
sortium. (2008). Genome-wide association defines more
than 30 distinct susceptibility loci for Crohn’s disease. Nat.
Genet. 40, 955–962.
30. Cookson,W., Liang, L., Abecasis, G., Moffatt, M., and Lathrop,
M. (2009). Mapping complex disease traits with global gene
expression. Nat. Rev. Genet. 10, 184–194.
31. Devlin, B., and Roeder, K. (1999). Genomic control for associ-
ation studies. Biometrics 55, 997–1004.
32. Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin,
R.M., Gibbs, R.A., Hurles, M.E., and McVean, G.A.; 1000
Genomes Project Consortium. (2010). A map of human
genome variation from population-scale sequencing. Nature
467, 1061–1073.
33. Lees, C.W., Barrett, J.C., Parkes, M., and Satsangi, J. (2011).
New IBD genetics: common pathways with other diseases.
Gut 60, 1739–1753.
34. Zhernakova, A., Stahl, E.A., Trynka, G., Raychaudhuri, S., Fes-
ten, E.A., Franke, L., Westra, H.J., Fehrmann, R.S., Kurreeman,
F.A., Thomson, B., et al. (2011). Meta-analysis of genome-wide
association studies in celiac disease and rheumatoid arthritis
identifies fourteen non-HLA shared loci. PLoS Genet. 7,
e1002004.
35. Cotsapas, C., Voight, B.F., Rossin, E., Lage, K., Neale, B.M.,
Wallace, C., Abecasis, G.R., Barrett, J.C., Behrens, T., Cho, J.,
et al.; FOCiS Network of Consortia. (2011). Pervasive sharing
of genetic effects in autoimmune disease. PLoS Genet. 7,
e1002254.
36. Donlin, L.T., Roman, C.A., Adlam, M., Regelmann, A.G., and
Alexandropoulos, K. (2002). Defective thymocyte maturation
by transgenic expression of a truncated form of the T lympho-
cyte adapter molecule and Fyn substrate, Sin. J. Immunol.
169, 6900–6909.
37. Donlin, L.T., Danzl, N.M., Wanjalla, C., and Alexandropoulos,
K. (2005). Deficiency in expression of the signaling protein
Sin/Efs leads to T-lymphocyte activation and mucosal inflam-
mation. Mol. Cell. Biol. 25, 11035–11046.
38. Muraoka, M., Hasegawa, H., Kohno, M., Inoue, A., Miyazaki,
T., Terada, M., Nose, M., and Yasukawa, M. (2006). IK cytokine
ameliorates the progression of lupus nephritis in MRL/lpr
mice. Arthritis Rheum. 54, 3591–3600.
39. Moriwaki, Y., Yoshikawa, K., Fukuda, H., Fujii, Y.X., Misawa,
H., and Kawashima, K. (2007). Immune system expression
of SLURP-1 and SLURP-2, two endogenous nicotinic acetyl-
choline receptor ligands. Life Sci. 80, 2365–2368.
40. Galitovskiy, V., Qian, J., Chernyavsky, A.I., Marchenko, S.,
Gindi, V., Edwards, R.A., and Grando, S.A. (2011). Cytokine-
induced alterations of a7 nicotinic receptor in colonic CD4
T cells mediate dichotomous response to nicotine in murineerican Journal of Human Genetics 92, 667–680, May 2, 2013 679
models of Th1/Th17- versus Th2-mediated colitis. J. Immunol.
187, 2677–2687.
41. Snoek, S.A., Verstege, M.I., van der Zanden, E.P., Deeks, N.,
Bulmer, D.C., Skynner, M., Lee, K., Te Velde, A.A., Boeckx-
staens, G.E., and de Jonge, W.J. (2010). Selective alpha7
nicotinic acetylcholine receptor agonists worsen disease in
experimental colitis. Br. J. Pharmacol. 160, 322–333.
42. Baranzini, S.E., Wang, J., Gibson, R.A., Galwey, N., Naegelin,
Y., Barkhof, F., Radue, E.W., Lindberg, R.L., Uitdehaag, B.M.,
Johnson, M.R., et al. (2009). Genome-wide association anal-
ysis of susceptibility and clinical phenotype in multiple
sclerosis. Hum. Mol. Genet. 18, 767–778.
43. Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-
Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al.
(2012). The genetic basis of early T-cell precursor acute
lymphoblastic leukaemia. Nature 481, 157–163.
44. Zeggini, E., Scott, L.J., Saxena, R., Voight, B.F., Marchini, J.L.,
Hu, T., de Bakker, P.I., Abecasis, G.R., Almgren, P., Andersen,
G., et al.; Wellcome Trust Case Control Consortium. (2008).
Meta-analysis of genome-wide association data and large-scale
replication identifies additional susceptibility loci for type 2
diabetes. Nat. Genet. 40, 638–645.
45. Schadt, E.E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum,
P.Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C., et al.
(2008). Mapping the genetic architecture of gene expression
in human liver. PLoS Biol. 6, e107.
46. Wang, Q., Levay, K., Chanturiya, T., Dvoriantchikova, G., An-
derson, K.L., Bianco, S.D., Ueta, C.B., Molano, R.D., Pileggi, A.,
Gurevich, E.V., et al. (2011). Targeted deletion of one or two
copies of the G protein b subunit Gb5 gene has distinct effects
on body weight and behavior in mice. FASEB J. 25, 3949–
3957.
47. Kopf, D., Cheng, L.S., Blandau, P., Hsueh, W., Raffel, L.J., Bu-
chanan, T.A., Xiang, A.H., Davis, R.C., Rotter, J.I., and Lehnert,
H. (2008). Association of insulin sensitivity and glucose toler-
ance with the c.825C>T variant of the G protein beta-3 sub-
unit gene. J. Diabetes Complications 22, 205–209.
48. Voight, B.F., Scott, L.J., Steinthorsdottir, V., Morris, A.P., Dina,
C., Welch, R.P., Zeggini, E., Huth, C., Aulchenko, Y.S., Thor-
leifsson, G., et al.; MAGIC investigators; GIANT Consortium.
(2010). Twelve type 2 diabetes susceptibility loci identified
through large-scale association analysis. Nat. Genet. 42,
579–589.
49. Langberg, K.A., Ma, L., Sharma, N.K., Hanis, C.L., Elbein, S.C.,
Hasstedt, S.J., and Das, S.K.; American Diabetes Association
GENNID Study Group. (2012). Single nucleotide polymor-
phisms in JAZF1 and BCL11A gene are nominally associated
with type 2 diabetes in African-American families from the
GENNID study. J. Hum. Genet. 57, 57–61.
50. Yang, X., Deignan, J.L., Qi, H., Zhu, J., Qian, S., Zhong, J., Tor-
osyan, G., Majid, S., Falkard, B., Kleinhanz, R.R., et al. (2009).
Validation of candidate causal genes for obesity that affect
shared metabolic pathways and networks. Nat. Genet. 41,
415–423.
51. Crowe, S., Wu, L.E., Economou, C., Turpin, S.M., Matzaris, M.,
Hoehn, K.L., Hevener, A.L., James, D.E., Duh, E.J., and Watt,
M.J. (2009). Pigment epithelium-derived factor contributes
to insulin resistance in obesity. Cell Metab. 10, 40–47.
52. Bo¨hm, A., Ordelheide, A.M., Machann, J., Heni, M., Ketterer,
C., Machicao, F., Schick, F., Stefan, N., Fritsche, A., Ha¨ring,
H.U., and Staiger, H. (2012). Common genetic variation in
the SERPINF1 locus determines overall adiposity, obesity-680 The American Journal of Human Genetics 92, 667–680, May 2, 2related insulin resistance, and circulating leptin levels. PLoS
ONE 7, e34035.
53. McKusick, V.A. (1998). Mendelian Inheritance in Man. A Cat-
alog of Human Genes and Genetic Disorders (Baltimore: John
Hopkins University Press).
54. Shen, L., Liu, X., Hou, W., Yang, G., Wu, Y., Zhang, R., Li, X.,
Che, H., Lu, Z., Zhang, Y., et al. (2010). NDRG2 is highly ex-
pressed in pancreatic beta cells and involved in protection
against lipotoxicity. Cell. Mol. Life Sci. 67, 1371–1381.
55. Miettinen, P.J., Ustinov, J., Ormio, P., Gao, R., Palgi, J., Hako-
nen, E., Juntti-Berggren, L., Berggren, P.O., and Otonkoski, T.
(2006). Downregulation of EGF receptor signaling in pancre-
atic islets causes diabetes due to impaired postnatal beta-cell
growth. Diabetes 55, 3299–3308.
56. Pritchard, J.K. (2001). Are rare variants responsible for suscep-
tibility to complex diseases? Am. J. Hum. Genet. 69, 124–137.
57. Ku, C.S., Loy, E.Y., Pawitan, Y., and Chia, K.S. (2010). The pur-
suit of genome-wide association studies: where are we now?
J. Hum. Genet. 55, 195–206.
58. Kiezun, A., Garimella, K., Do, R., Stitziel, N.O., Neale, B.M.,
McLaren, P.J., Gupta, N., Sklar, P., Sullivan, P.F., Moran, J.L.,
et al. (2012). Exome sequencing and the genetic basis of com-
plex traits. Nat. Genet. 44, 623–630.
59. Suhre, K., Shin, S.Y., Petersen, A.K., Mohney, R.P., Meredith,
D., Wa¨gele, B., Altmaier, E., Deloukas, P., Erdmann, J., Grund-
berg, E., et al.; CARDIoGRAM. (2011). Human metabolic indi-
viduality in biomedical and pharmaceutical research. Nature
477, 54–60.
60. Gibbs, J.R., van der Brug, M.P., Hernandez, D.G., Traynor, B.J.,
Nalls, M.A., Lai, S.L., Arepalli, S., Dillman, A., Rafferty, I.P.,
Troncoso, J., et al. (2010). Abundant quantitative trait loci
exist for DNA methylation and gene expression in human
brain. PLoS Genet. 6, e1000952.
61. Schadt, E.E. (2009). Molecular networks as sensors and drivers
of common human diseases. Nature 461, 218–223.
62. Wang, K., Zhang, H., Kugathasan, S., Annese, V., Bradfield, J.P.,
Russell, R.K., Sleiman, P.M., Imielinski, M., Glessner, J., Hou,
C., et al. (2009). Diverse genome-wide association studies asso-
ciate the IL12/IL23 pathway with Crohn disease. Am. J. Hum.
Genet. 84, 399–405.
63. Grundberg, E., Small, K.S., Hedman, A.K., Nica, A.C., Buil, A.,
Keildson, S., Bell, J.T., Yang, T.P., Meduri, E., Barrett, A., et al.;
Multiple Tissue Human Expression Resource (MuTHER)
Consortium. (2012). Mapping cis- and trans-regulatory ef-
fects across multiple tissues in twins. Nat. Genet. 44, 1084–
1089.
64. Fehrmann, R.S., Jansen, R.C., Veldink, J.H., Westra, H.J.,
Arends, D., Bonder, M.J., Fu, J., Deelen, P., Groen, H.J., Smo-
lonska, A., et al. (2011). Trans-eQTLs reveal that independent
genetic variants associated with a complex phenotype
converge on intermediate genes, with a major role for the
HLA. PLoS Genet. 7, e1002197.
65. Small, K.S., Hedman, A.K., Grundberg, E., Nica, A.C., Thor-
leifsson, G., Kong, A., Thorsteindottir, U., Shin, S.Y., Richards,
H.B., Soranzo, N., et al.; GIANT Consortium; MAGIC Investi-
gators; DIAGRAMConsortium; MuTHER Consortium. (2011).
Identification of an imprinted master trans regulator at the
KLF14 locus related to multiple metabolic phenotypes. Nat.
Genet. 43, 561–564.
66. Slager, S.L., and Schaid, D.J. (2001). Case-control studies of
genetic markers: power and sample size approximations for
Armitage’s test for trend. Hum. Hered. 52, 149–153.013
